Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
ORGANIZATION
Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
The Japanese government should take a realistic approach as to supply chain surveys that would be requested for the pharma industry under its envisaged economic security legislation, a Japan Pharmaceutical Manufacturers Association (JPMA) official urged in a recent interview. “How…
To read the full story
Related Article
- MHLW Details Plan to Ensure Stable Supplies of β-Lactam Antibiotics
January 24, 2023
- Japan Designates Antibiotics as Key Resources for Economic Security
December 21, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
- Govt Plans to Designate Key Resources Before End of Year: Minister
October 4, 2022
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- Guidelines for Securing Key Resources Endorsed by LDP, Up for Cabinet Approval
July 20, 2022
- All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Japan Enacts Economic Security Law; Supply Chain Clauses to Take Effect in 9 Months after Promulgation
May 12, 2022
- Lower House OKs Economic Security Bill
April 8, 2022
- PM Vows Effective Supply Chain Surveys as Economic Security Bill Enters Diet
March 18, 2022
- Economic Security Bill to Enter Diet Deliberations on March 17
March 17, 2022
- Japan Cabinet OKs Draft Economic Security Bill
February 28, 2022
- Key Resource Suppliers to Be Fined for False Reporting: Draft Economic Security Bill
February 17, 2022
- Will New Economic Security Bill Contribute to Ensuring Stable Drug Supplies?
February 16, 2022
- Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
- Govt Panel Proposes Enhanced Pharma Supply Chain through Economic Security Bill
February 2, 2022
- Govt Panel Compiles Draft Proposal for Bill to Bolster Supply Chains for Drugs, Essential Resources
January 21, 2022
- Japan to Beef Up Pharma Supply Chain through Economic Security Bill
January 19, 2022
ORGANIZATION
- Japan Pharmacy Group Demands Abolishing Off-Year Price Revisions
November 22, 2024
- Chuikyo Payer Rep Touts Necessity of FY2025 Off-Year Price Revision
November 19, 2024
- Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
- JPMA Appreciates Growing Calls for Abolition of Off-Year Revisions: Exec
November 15, 2024
- Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator
November 12, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…